Effect of hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial, an update with an intention-to-treat analysis and clinical outcomes.
作者信息
Gautret Philippe, Hoang Van Thuan, Lagier Jean-Christophe, Raoult Didier
机构信息
IHU-Méditerranée Infection, Marseille, France; Aix Marseille Univ, IRD, AP-HM, SSA, VITROME, Marseille, France.
IHU-Méditerranée Infection, Marseille, France; Aix Marseille Univ, IRD, AP-HM, SSA, VITROME, Marseille, France; Thai Binh University of Medicine and Pharmacy, Thai Binh, Vietnam.
出版信息
Int J Antimicrob Agents. 2021 Jan;57(1):106239. doi: 10.1016/j.ijantimicag.2020.106239.
Abstract
摘要
相似文献
1
Effect of hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial, an update with an intention-to-treat analysis and clinical outcomes.
Int J Antimicrob Agents. 2021 Jan;57(1):106239. doi: 10.1016/j.ijantimicag.2020.106239.
2
Interpretation of SARS-CoV-2 PCR results for the diagnosis of COVID-19.
Int J Antimicrob Agents. 2021 Jan;57(1):106238. doi: 10.1016/j.ijantimicag.2020.106238.
3
Effect of hydroxychloroquine and azithromycin on SARS-CoV-2 clearance in COVID-19 patients, a meta-analysis.
Int J Antimicrob Agents. 2021 Jan;57(1):106240. doi: 10.1016/j.ijantimicag.2020.106240.
4
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open label non-randomized clinical trial revisited.
Int J Antimicrob Agents. 2021 Jan;57(1):106243. doi: 10.1016/j.ijantimicag.2020.106243.
5
Clinical efficacy and safety profile of hydroxychloroquine and azithromycin against COVID-19.
Int J Antimicrob Agents. 2021 Jan;57(1):106242. doi: 10.1016/j.ijantimicag.2020.106242.
6
Effect estimation of hydroxychloroquine for COVID-19: a secondary analysis of an open label non-randomized clinical trial.
Int J Antimicrob Agents. 2021 Jan;57(1):106172. doi: 10.1016/j.ijantimicag.2020.106172.
7
Focus on clinical outcomes of "Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial".
Int J Antimicrob Agents. 2021 Jan;57(1):106175. doi: 10.1016/j.ijantimicag.2020.106175.
8
Letter to the editor about "Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial".
Int J Antimicrob Agents. 2021 Jan;57(1):106171. doi: 10.1016/j.ijantimicag.2020.106171.
9
Referring to the study: Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open label non-randomized clinical trial.
Int J Antimicrob Agents. 2021 Jan;57(1):106176. doi: 10.1016/j.ijantimicag.2020.106176.
10
Uncertain effects of hydroxychloroquine and azithromycin on SARS-Cov-2 viral load.
Int J Antimicrob Agents. 2021 Jan;57(1):106169. doi: 10.1016/j.ijantimicag.2020.106169.
引用本文的文献
1
Antibiotics Use in COVID-19 Patients: A Systematic Literature Review.
J Clin Med. 2022 Dec 4;11(23):7207. doi: 10.3390/jcm11237207.
2
A Review Pertaining to SARS-CoV-2 and Autoimmune Diseases: What Is the Connection?
Life (Basel). 2022 Nov 18;12(11):1918. doi: 10.3390/life12111918.
3
SHEA statement on antibiotic stewardship in hospitals during public health emergencies.
Infect Control Hosp Epidemiol. 2022 Nov;43(11):1541-1552. doi: 10.1017/ice.2022.194. Epub 2022 Sep 14.
4
WHO Ordinal Scale and Inflammation Risk Categories in COVID-19. Comparative Study of the Severity Scales.
J Gen Intern Med. 2022 Jun;37(8):1980-1987. doi: 10.1007/s11606-022-07511-7. Epub 2022 Apr 8.
5
Population Pharmacokinetics of Hydroxychloroquine and 3 Metabolites in COVID-19 Patients and Pharmacokinetic/Pharmacodynamic Application.
Pharmaceuticals (Basel). 2022 Feb 21;15(2):256. doi: 10.3390/ph15020256.
6
A Peek into Pandora's Box: COVID-19 and Neurodegeneration.
Brain Sci. 2022 Jan 30;12(2):190. doi: 10.3390/brainsci12020190.
7
Efficacy of chloroquine and hydroxychloroquine for the treatment of hospitalized COVID-19 patients: a meta-analysis.
Future Virol. 2021 Nov. doi: 10.2217/fvl-2021-0119. Epub 2021 Dec 3.
8
The immunomodulatory effects of macrolide antibiotics in respiratory disease.
Pulm Pharmacol Ther. 2021 Dec;71:102095. doi: 10.1016/j.pupt.2021.102095. Epub 2021 Nov 3.
9
A short focus, azithromycin in the treatment of respiratory viral infection COVID-19: efficacy or inefficacy?
Immunol Res. 2022 Feb;70(1):129-133. doi: 10.1007/s12026-021-09244-x. Epub 2021 Nov 5.
10
The Use of Corticosteroids or Tocilizumab in COVID-19 Based on Inflammatory Markers.
J Gen Intern Med. 2022 Jan;37(1):168-175. doi: 10.1007/s11606-021-07146-0. Epub 2021 Oct 18.
本文引用的文献
1
Letter to the editor about "Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial".
Int J Antimicrob Agents. 2021 Jan;57(1):106171. doi: 10.1016/j.ijantimicag.2020.106171.
2
Outcomes of 3,737 COVID-19 patients treated with hydroxychloroquine/azithromycin and other regimens in Marseille, France: A retrospective analysis.
Travel Med Infect Dis. 2020 Jul-Aug;36:101791. doi: 10.1016/j.tmaid.2020.101791. Epub 2020 Jun 25.
3
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Int J Antimicrob Agents. 2020 Jul;56(1):105949. doi: 10.1016/j.ijantimicag.2020.105949. Epub 2020 Mar 20.
4
Novel coronavirus infection during the 2019-2020 epidemic: preparing intensive care units-the experience in Sichuan Province, China.
Intensive Care Med. 2020 Feb;46(2):357-360. doi: 10.1007/s00134-020-05954-2. Epub 2020 Feb 5.
Zotero 插件